Popular terms

G Protein topics
Antibodies
Nucleic Acid
G Proteins
Nucleic Acids
Amino Acid
Polypeptide
Protein A Affinity Chromatography
Chromatography
Chromatograph
Liver Metastasis
Membrane Protein
Colorectal Carcinoma
Rectal Carcinoma
Prophylactic
Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Protein patents



      

This page is updated frequently with new G Protein-related patent applications.




Date/App# patent app List of recent G Protein-related patents
07/21/16
20160210874 
 System and  increasing learning through eating protein, exercising, and singing and preventing bullying patent thumbnailnew patent System and increasing learning through eating protein, exercising, and singing and preventing bullying
A system and method of enhancing learning through a combination exercising, singing, and eating protein is provided. The method includes the steps of exercising in place for five minutes, singing a song, sitting in silence, eating the protein-based food, and commencing a teaching or training session.

07/21/16
20160210399 
 Methods and  predicting protein structure patent thumbnailnew patent Methods and predicting protein structure
The present invention relates to a method for predicting three-dimensional structure of a protein from its sequence. Three-dimensional structure may be determined by: (a) generating a multiple sequence alignment for a candidate protein having a known sequence; (b) identifying a covariance matrix between all pairs of sequence positions in the multiple sequence alignment; (c) inverting the covariance matrix and identifying predicted evolutionary constraints using a statistical model of the candidate protein; and (d) simulating folding of an extended chain structure of the candidate protein using the predicted constraints..
President And Fellows Of Harvard College


07/21/16
20160208405 
 Foam-jetting member for protein crystal device and protein crystal-adsorbing foam-jetting member, protein crystal device and  crystallizing protein, and protein crystal cutting device and  cutting protein crystal patent thumbnailnew patent Foam-jetting member for protein crystal device and protein crystal-adsorbing foam-jetting member, protein crystal device and crystallizing protein, and protein crystal cutting device and cutting protein crystal
Provided are a protein crystal device and method for crystallizing protein capable of generating protein crystal without imparting a heat effect, a protein crystal-cutting device and method for cutting protein crystal capable of cutting protein crystal without imparting a heat effect on protein crystal, and bubble-jetting member and protein-adsorbing-bubble-jetting member used in said device. A bubble-jetting member is used in a protein crystal device to jet bubbles into a protein solution to thereby allow protein crystals to be obtained, the bubble-jetting member comprising: a core formed of a conductive material; a shell part formed of an insulating material, including an extended section extending from the tip of the core, and in which at least a portion closely adheres to the core to cover the core; and a gap having a bubble-jetting port, the gap being formed between the extended section and the tip of the core..
Japan Science And Technology Agency


07/21/16
20160208274 
 Blood clot-dissolving proteins produced in seeds patent thumbnailnew patent Blood clot-dissolving proteins produced in seeds
Transgenic plants in which blood-clot dissolving proteins are produced in seeds of the plants are provided. Expression of the proteins is driven by a seed specific or selective promoter.
Northeastern State University


07/21/16
20160207962 
 Electron spin labeled ice binding compounds used for carrying paramagnetic centers for dynamic nuclear polarization patent thumbnailnew patent Electron spin labeled ice binding compounds used for carrying paramagnetic centers for dynamic nuclear polarization
Spin labeled ice binding compounds (ibcs) including ice binding proteins (ibps), also called antifreeze proteins (afps) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (dnp), for enhancing nuclear magnetic resonance (nmr) signal intensities. Use of spin labeled ibcs to perform dnp exploits the ibcs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high dnp efficiency.
The Trustees Of California State University


07/21/16
20160207960 
 Peptides inhibiting cold-inducible rna binding protein activity patent thumbnailnew patent Peptides inhibiting cold-inducible rna binding protein activity
Disclosed are pharmaceutical compositions comprising a cirp inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a cirp inhibitor are also described herein..
The Feinstein Institute For Medical Research


07/21/16
20160207912 
 Heteroaryl amides as inhibitors of protein aggregation patent thumbnailnew patent Heteroaryl amides as inhibitors of protein aggregation
The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as parkinson's disease, alzheimer's disease, lewy body disease, parkinson's disease with dementia, fronto-temporal dementia, huntington's disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.. .
Neuropore Therapies, Inc.


07/21/16
20160206679 
 Materials and methods for modulating disc1 turnover patent thumbnailnew patent Materials and methods for modulating disc1 turnover
The invention relates to the finding that turnover of disc1 (disrupted in schizophrenia 1) is mediated by the f-box-containing protein fbxw7 (f-box/wd repeat-containing protein 7). The sequence within disc1 that binds to fbxw7 and targets disc1 for turnover by the ubiquitin-proteasome system is identified.
The University Court Of The University Of Glasgow


07/21/16
20160206592 
 Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling patent thumbnailnew patent Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling
The present invention provides use of an inhibitor of g protein-coupled receptor cxcr4 for treating amyotrophic lateral sclerosis (als), for inhibiting glutamate release in astrocytes, or for increasing remyelinization in motor neurons.. .
Ramot At Tel-aviv University Ltd.


07/14/16
20160202276 
 Solution for dissociating vitamin d from vitamin d-biding protein, associated detection method and use patent thumbnailSolution for dissociating vitamin d from vitamin d-biding protein, associated detection method and use
At least one fluoroalkyl surfactant and of at least one alcohol having 1 to 4 carbon atoms are used for dissociating vitamin d and/or a vitamin d metabolite from vitamin d binding protein. A solution comprising the at least one fluoroalkyl surfactant and at least one alcohol is provided.
BiomÉrieux


07/14/16
20160202274 

Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers


The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The Unversity Of Oxford


07/14/16
20160202234 

Method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation


The invention relates to a method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation. Said method comprises: a) sampling, in at least one area of the body of the person, the follicles or bulbs of head and/or body hair of the person; b) extracting proteins from cells of said sampled hair bulbs or follicles, wherein said proteins, including proteins from the atm system, are subjected to phosphorylation and/or acetylation induced by ionizing radiation; and c) analyzing at least two types of extracted proteins and interpreting the analysis results in order to determine the irradiation dose in the or each sampling area..
Acubens


07/14/16
20160201111 

Method and measuring protein post-translational modification


The present invention includes a method for analyzing reactions. The method includes the steps of providing a solution of at least one acceptor chemical and at least one donor chemical.
Icagen, Inc.


07/14/16
20160201031 

Composition and methods for culturing cells


The present disclosure provides compositions for in vitro culture of cells. The present disclosure provides methods for in vitro culture of cells.
The Regents Of The University Of California


07/14/16
20160200847 

Clickable polymers and gels for microarray and other applications


Fabrication of arrays, including glycan arrays, that combines the higher sensitivity of a layered si—sio2 substrate with novel immobilization chemistry via a “click” reaction. The novel immobilization approach allows the oriented attachment of glycans on a “clickable” polymeric coating.

07/14/16
20160200830 

Compositions and methods for increasing protein half-life in a serum


Novel antibodies, such as single domain antibodies (sdabs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described..
Nanjingjinsirui Science & Technology Biology Corporation


07/14/16
20160200823 

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof


This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a cd154 (cd40l) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized fab fragment comprising a variable heavy chain sequence according to seq id no: 1 and comprising a variable light chain sequence according to seq id no: 2 specifically binds.
Biogen Idec Ma Inc.


07/14/16
20160200813 

Lrp-8 binding proteins


The disclosure provides binding proteins that specifically bind to lrp-8 and optionally cross the blood brain barrier (bbb), localize to the brain and/or localize to the spinal cord.. .
Abbvie Inc.


07/14/16
20160200811 

Dual variable region antibody-like binding proteins having cross-over binding region orientation


The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins..
Sanofi


07/14/16
20160200796 

Fusion protein comprising albumin and retinol-binding protein


There is provided a fusion protein comprising albumin and retinol-binding protein (rbp), which can be used for preventing or treating fibrotic diseases. The fusion protein, in which albumin and rbp are bound together, is incorporated into stellate cells and induces phenotypic reversion from myofibroblast-like cells to quiescent fat-storing phenotype.
Korea University Research And Business Foundation


07/14/16
20160199500 

Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof


A system for detecting cancer cells that targets the cubilin receptor for the vitamin b12 binding protein, intrinsic factor. A b12 conjugate and intrinsic factor is injected into the blood of a patient.
Syracuse University


07/14/16
20160199494 

Compositions and methods for stabilizing protein-containing formulations


The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.. .
Genentech, Inc.


07/14/16
20160199443 

Polypeptide targeting to mitochondria


Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a dna-binding polypeptide, fused to a mitochondrial targeting sequence (mts) and a nuclear export signal (nes), and the encoded proteins.
Medical Research Council


07/14/16
20160199441 

Pan-antiviral peptides for protein kinase inhibition


A method of inhibiting protein kinases by administering polypeptides derived from alpha-neurotoxin, and inhibiting protein kinases. Diseases treated thereby include cancer, influenza, tourette's syndrome, pain, and neurological deficits..
Nuovo Biologics, Llc


07/14/16
20160199408 

Compositions containing nucleosides and manganese and their uses


This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e g., manganese) to a subject in need thereof.
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services


07/14/16
20160198737 

Method for recovering proteins from waste water discharged during process of producing fish meat processed product


According to the present invention, a method for recovering useful fish meat proteins from waste water generated during fish paste or fishmeal production is provided. The provided is a method for recovering water-soluble proteins from fish paste leaching waste water or stick water, comprising: adjusting the ph of fish paste leaching waste water or stick water to 4.5-5.5 to insolubilize water-soluble proteins; heating the insolubilized proteins to 30° c.
Maruha Nichiro Corporation


07/07/16
20160195535 

Method for detecting prostatic basal cells


The purpose of the present invention is to provide a method for detecting prostatic basal cells by searching for molecules that are expressed specifically in prostatic basal cells and analyzing said molecules. The problem can be solved using a method for detecting prostatic basal cells that is characterized by using immunohistochemical staining to visualize the expression of trim29 (tripartite motif-containing protein 29) protein in prostatic basal cells..
Lsip, Llc


07/07/16
20160195525 

Diagnosis and treatment of mycobacteria infections


The invention provides isolated, purified, recombinant receptor binding proteins gp-6, gp-10 and gp-31 from mycobacterium phage l5, and methods for producing these recombinant receptor binding proteins. The invention also provides the use of recombinant receptor binding proteins, including gp-6, gp-10 and gp-31, as probes for the identification and diagnosis of mycobacterium infections and conditions caused by mycobacterium.
The Governors Of The University Of Alberta


07/07/16
20160194679 

Process for producing protein concentrate or isolate and cellulosic thermochemical feedstock from distillers grains


A process for treating distillers grains to produce a high value protein product and a cellulosic residue both from distillers grains. The high value protein product is useful as a protein supplement or feed for livestock and poultry and the cellulosic residue has value as a feedstock for a thermochemical process unit for the production of a biofuel..

07/07/16
20160194606 

Methods for inducing the differentiation of blood monocytes into functional dendritic cells


Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins.
Yale University


07/07/16
20160194409 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


07/07/16
20160194397 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


07/07/16
20160193358 

Antigen binding proteins


The present invention concerns antigen binding proteins and fragments thereof which specifically bind b cell maturation antigen (bcma), particularly human bcma (hbcma) and which inhibit the binding of baff and april to the bcma receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods..
Glaxo Group Limited


07/07/16
20160193292 

Cell permeable inhibitors of the scaffold protein plenty of sh3 domains (posh) or sh3rfl


Plenty of sii3 (posh) and ink-interacting protein 1 (jip-1) function as a multi-protein scaffold network for tcr-mediated jnk1 activation in cd8+ t-cells. Disruption of the posh/jip-1 complex led to profound defects in the activation of jnk1, as well as deficient activation or induction of the transcription factors c-jun, t-bet and eomesodermin furthermore, disruption of the posh/jip complex in cd8+t-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors.
The Curators Of The University Of Missouri


07/07/16
20160193266 

Method and smoke-infusing proteinaceous foods and smoked-infused such proteinaceous food product so-obtained


A method of smoke-infusing proteinaceous foods comprises the following sequential steps: a) enclosing the proteinaceous foods in a vacuum-treating zone; b) introducing smoke directly or indirectly from a smoke generation zone into the vacuum-treating zone; c) subjecting the proteinaceous foods to vacuum purging at a negative pressure in the vacuum-treating zone, thereby infusing smoke into the proteinaceous foods; d) repeating the steps of introducing smoke directly or indirectly from the smoke generation zone into the vacuum-treating zone; subjecting the proteinaceous foods to vacuum purging at a negative pressure in the vacuum-treating zone at least fifty times in pulsed sequences of smoke introduction stage/vacuum purging stage/vacuum release stage for the efficient infusion of smoke into the proteinaceous foods; and e) a post-chill resting cycle of the smoke-infused proteinaceous foods at a suitable temperature and for a suitable period of time. An optional modification to the smoke-infusing process is the addition of cannabis plant material in order to enable the deposition of cannabis-derived compounds on the surface of the smoke-infused food..

07/07/16
20160193168 

Treatment of pulmonary arterial hypertension with leukotriene inhibitors


Pulmonary arterial hypertension (pah) can be prevented in persons susceptible to the diseases and pah patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene a4 hydrolase (lta4h) inhibitors, leukotriene b4 receptor (blt1/blt2) antagonists, 5-lipoxygenase (5-lo) inhibitors, and 5-lipoxgygenase activating protein (flap) inhibitors..
The Board Of Trustees Of The Leland Stanford Junior University


07/07/16
20160193150 

Reducing or non-reducing polynucleotide polymer for drug delivery and preparing same


The present invention relates to a reducing or non-reducing polynucleotide polymer for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer. The present invention relates to a drug delivery carrier for delivering proteins or peptides to a targeted area through electrostatic attraction, by obtaining a negatively (−) charged polymer by using nucleotides to synthesize the reducing or non-reducing polymer, which is easily breakable due to disulfide bonds, and then bonding the negatively (−) charged polymer with a positively (+) charged protein or peptide, wherein a polymer derived from a non-viral drug delivery carrier containing the novel reducing or non-reducing polymer is capable of effectively enabling escape of a drug, delivered by means of proton buffering activity, from an endosome to other organelles in a cell..
Utah-inha Dds & Advanced Therapeutics Research Center


07/07/16
20160192697 

Protein-enriched tobacco-derived composition


The present disclosure describes methods of obtaining and/or deriving proteins from plants of the nicotiana species and methods for incorporation of such proteins into various products. For example, a method for obtaining a protein-enriched material from a plant of the nicotiana species or portion thereof is provided, comprising: extracting one or more proteins from the plant material into a solvent to form a liquid protein-containing extract; separating a solid extracted plant material from the liquid protein-containing extract; clarifying the liquid protein-containing extract to form a clarified protein-containing extract and a solids fraction; and treating the clarified protein-containing extract so as to provide a protein-enriched material comprising at least about 60% protein by weight..
R.j. Reynolds Tobacco Company


07/07/16
20160192674 

Chewing gum composition comprising a micro-encapsulated flavour in a matrix comprising protein


A chewing gum composition comprising; (a) a gum base; and (b) at least one microencapsulated composition comprising at least one active component and a matrix to at least partially microencapsulate the at least one active component; the at least one active component comprising at least one oil-soluble flavoring agent and the matrix comprising dewatered protein precipitate.. .
Intercontinental Great Brands Llc


07/07/16
20160192671 

Protein products and methods for making the same


According to one embodiment, a protein product may include a mixture of water and particulate matter comprising protein. The mixture may include medium chain aldehydes and pyrazines.
Kraft Foods Group Brands Llc


06/30/16
20160187357 

Compositions and methods for increasing bone mineralization


A novel class or family of tgf-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules..

06/30/16
20160187321 

Induced expression of proteins in insect cells


The present invention concerns insect cells that have been induced to express one or more proteins by contact with one or more insect hormones or one or more modulators of the g protein-coupled receptor signaling pathway, compositions comprising such insect cells, a method for inducing protein expression in insect cells, and a screening method using such insect cells.. .

06/30/16
20160187319 

Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth


An agent for inducing cell death and/or inhibiting cell growth for cancer cells. The agents of the present invention comprise, as active ingredients, a drug inhibiting gst-π and a drug inhibiting a homeostasis-related protein that exhibits synthetic lethality when inhibited together with gst-π.

06/30/16
20160186269 

Novel translocations in lung cancer


The invention relates to methods for determining the presence or absence of striatin-anaplastic lymphoma kinase (strn-alk) gene fusion and/or a fibroblast growth factor receptor 3—transforming acidic coiled-coil containing protein 3 (fgfr3-tacc3) gene fusion in an individual, especially an individual suffering from lung cancer. The invention further relates to a method for diagnosing an individual as having adenocarcinoma, and to a method for treating said individual.

06/30/16
20160186164 

Thermostable blunt-end ligase and methods of use


Thermostable blunt-end ligases suitable for use in nucleic acid ligation reactions at elevated temperatures are provided. The ligases comprise fusion proteins including a dna ligase and a dna binding protein, e.g., a t4 dna ligase with an n-terminal p50 fusion.

06/30/16
20160186157 

Intein-modified enzymes, their production and industrial application


A method of predicting an intein insertion site in a protein that will lead to a switching phenotype is provided. The method includes identifying a plurality of c/t/s sites within the protein; selecting from the plurality of c/t/s/sites those that are ranked 0.75 or higher by a support vector machine, within ten angstroms of the active site of the protein, and at or near a loop-β-sheet junction or a loop-α-helix junction.

06/30/16
20160185795 

Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors


Wherein r1, r2, r3, r4, w, a and b are as described herein, compositions including the compounds and methods of using the compounds.. .

06/30/16
20160185753 

Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds


Deuterated diaminopyrimidine compounds and pharmaceutical compositions containing such compounds are described. In particular, disclosed are deuterated diaminopyrimidine compounds of formula (i), and pharmaceutical compositions containing such compounds or crystal forms, pharmaceutically acceptable salt, hydrates or solvates thereof.

06/30/16
20160185725 

C-met modulators and use


The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-met, kdf, c-kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

06/30/16
20160184413 

Formulation for stabilizing proteins, which is free of mammalian excipient


The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, wherein the formulation is free of stabilising proteins.. .

06/30/16
20160184407 

Novel class of therapeutic protein based molecules


The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus.

06/30/16
20160184274 

Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition


Methods of using inhibitors of goodpasture antigen binding protein for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition (emt), treating an invasive tumor, and detecting emt in a tissue are described.. .

06/23/16
20160177336 

Expression tools for multiprotein applications


Polynucleotides for multigene applications comprising a novel functional arrangement, as well as vectors, host cells, and recombinant animals comprising the polynucleotides are described. Methods for generating multigene expression cassettes, methods for producing multiprotein complexes in vitro and in vivo, and methods for producing a vaccine are also disclosed.

06/23/16
20160177328 

Plants having one or more enhanced yield-related traits and a making the same


A method for enhancing various economically important yield-related traits in plants. A method for enhancing one or more yield-related traits in plants by modulating expression in plants of a nucleic acid encoding a fkbp 16-3 (fk506-binding protein) or a quinone reductase-related (qrr) polypeptide.

06/23/16
20160177300 

Means and methods for the generation of mammalian producer cells for the production of recombinant proteins


The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.. .

06/23/16
20160176977 

Novel acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer


A novel gene 0161p2f10b (also designated 161p2f10b) and its encoded protein, and variants thereof, are described wherein 161p2f10b exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i. Consequently, 161p2f10b provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.

06/23/16
20160176971 

Methods and compositions relating to anti-il-21 receptor antibodies


The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .

06/23/16
20160176958 

Tnf-alpha binding proteins


Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (tnf-α), e.g., human tnf-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies..

06/23/16
20160176946 

Process for preparing apolipoprotein a-i (apo a-i)


The present invention relates to processes of obtaining apo a-1 from an apo a-1 containing protein fraction (a), comprising suspending—the apo a-1 containing protein fraction (a) in a buffer solution (b), removing impurities from the suspension while keeping the apo a-1 proteins solubilized, followed by precipitating apo a˜i from the suspension and collecting the apo a-1 precipitate. Apo a-i obtained by such processes, reconstituted hdl obtained from such apo a-1, and pharmaceutical compositions comprising such apo a-i and/or reconstituted hdl also are provided..

06/23/16
20160174599 

Beverage lowering serum cholesterol


A beverage comprising protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser.. .

06/16/16
20160169910 

Non-glycosylated supar biomarkers and uses thereof


Proteinuria markers and methods for their use are provided. These markers find many uses, including in diagnosing proteinuria, prognosing proteinuria, and treating proteinuria.
Rush University Medical Center


06/16/16
20160168593 

Methods and compositions for enhancing targeted transgene integration


Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of r loop formation or inhibitors of r-loop repair and/or one or more up-regulators of the tc-ner pathway to the target cell.. .
Sangamo Biosciences, Inc.


06/16/16
20160168563 

Efficient displaying protein multimer


The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component.
Genefrontier Corporation


06/16/16
20160168559 

Biocatalytical composition


The present invention relates to means and methods for protecting proteins and protein-type compounds in industrial and other applications. In particular, the invention provides a composition comprising at least one protein or protein-type compound immobilized at the surface of a solid carrier embedded in a protective material.
Inofea Gmbh


06/16/16
20160168264 

Antibodies directed to her-3 and uses thereof


The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


06/16/16
20160168227 

Composition and vaccine for treating lung cancer


The present invention relates to a composition comprising at least one mrna encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5t4 (trophoblast glycoprotein, tpbg), survivin (baculoviral tap repeat-containing protein 5; birc5), ny-eso-1 (new york esophageal squamous cell carcinoma 1, ctag1b), mage-c1 (melanoma antigen family c1), mage-c2 (melanoma antigen family c2), and muc1 (mucin 1). The invention furthermore relates to a vaccine comprising at least one mrna encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (nsclc), and diseases or disorders related thereto.
Curevac Ag


06/16/16
20160168205 

Methods and compositions for labeling polypeptides


Synthesis of many proteins is tightly controlled at the level of translation and plays an essential role in fundamental processes such as cell growth and proliferation, signaling, differentiation or death. Methods that allow imaging and identification of nascent proteins allow for dissecting regulation of translation, both spatially and temporally, including in whole organisms.
President And Fellows Of Harvard College


06/16/16
20160168194 

Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation


06/16/16
20160168154 

Inhibitors of transcription factors and uses thereof


The present invention provides novel compounds of any one of formulae (i) to (iv), and pharmaceutically compositions thereof. Compounds of any one of formulae (i) to (iv) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (bets)).
University Of Massachusetts


06/16/16
20160166663 

Vaccine formulations that induce a th2 immune response


The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


06/16/16
20160166645 

Treatment of collagen defects using protein solutions


Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group il-1ra, stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii..
Biomet Biologics, Llc




G Protein topics: Antibodies, Nucleic Acid, G Proteins, Nucleic Acids, Amino Acid, Polypeptide, Protein A Affinity Chromatography, Chromatography, Chromatograph, Liver Metastasis, Membrane Protein, Colorectal Carcinoma, Rectal Carcinoma, Prophylactic, Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7947

4631

3 - 0 - 102